Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)–paclitaxel or docetaxel adjuvant chemotherapy in breast cancer

Abstract

BackgroundResults of CALGB 9741 demonstrated that administering standard doxorubicin/cyclophosphamide (AC)–paclitaxel therapy for adjuvant therapy of breast cancer in a dose-dense fashion with colony-stimulating factors increases efficacy, decreases severe neutropenia, but may increase the need for blood transfusions. A chart review was performed to evaluate the rates of anemia, neutropenia and skin toxicities with dose-dense and traditional AC–taxane chemotherapy. Patients and methodsA total of 112 patients received one of four treatments: non-dose-dense AC–paclitaxel (NDD Pac), dose-dense AC–paclitaxel (DD Pac), non dose-dense AC–docetaxel (NDD Doc), or dose-dense AC–docetaxel (DD Doc). ResultsTransfusion rates were not increased in the dose-dense population; however, rates of grade 2–4 anemia (23% versus 0%, P=0.029), as well as erythropoietin use (58% versus 0%, P<0.0001), were significantly increased in the DD Pac group compared with the NDD Pac group. Grade 3 skin toxicities were significantly increased in the DD Doc group compared with the NDD Doc group (70% versus 11%, P<0.0001). ConclusionsThese results demonstrate that dose-dense AC–taxane therapy may increase rates of anemia and the need for erythropoietin, and decrease rates of neutropenia. The utility of DD Doc appears limited by skin toxicities and its use outside of a clinical study should not be recommended.